Navigation Links
Muscular Dystrophy Association Awards $13.7 Million for 40 New Research Grants

TUCSON, Ariz., Aug. 23, 2011 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association today announced funding, totaling $13.7 million, for 40 new research initiatives targeting nearly two dozen progressive neuromuscular diseases.  Among these are 13 new initiatives targeting Duchenne muscular dystrophy (DMD), nine new projects focused on ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease), as well as efforts on spinal muscular atrophy (SMA), facioscapulohumeral muscular dystrophy (FSHD), and the link between diabetes and Friedreich's ataxia (FA).

These new projects are in addition to hundreds of other MDA-funded scientific investigations being advanced worldwide to find effective treatments for neuromuscular diseases.  

"Truly rapid progress is being made in the fight against muscular dystrophy, ALS and related diseases," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors.  "And MDA will not stop until these diseases are conquered."

This latest round of peer-reviewed grants recommended by the Association's Medical and Scientific Advisory Committees comprising the world's top medical and scientific authorities was approved for funding by the MDA Board of Directors. The promising new initiatives are underway in 17 U.S. cities, the District of Columbia, as well as in Australia, Canada, Costa Rica, Italy, the Netherlands and the United Kingdom:Baltimore, Md. (Grants 1, 2)

La Jolla, Calif. (Grants 1, 2, 3)

Genova, ItalyBoston, Mass. (Grants 1. 2, 3, 4, 5, 6)

Los Angeles, Calif.

Leiden, NetherlandsChicago, Ill.

Miami, Fla.

London, United KingdomColumbus, Ohio

Minneapolis, Minn.

Ottawa, CanadaDallas, Texas

New York, N.Y.

Perth, AustraliaDavis, Calif.

Newark, N.J.

Quebec City, CanadaDistrict of Columbia

Palo Alto, Calif.

Sydney, AustraliaHouston, Texas (Grants 1, 2, 3, 4)

Philadelphia, Pa. (Grants 1, 2)

San Pedro, Costa RicaIowa City, Iowa

Winston-Salem, N.C.

Victoria, Australia (Grants 1, 2)In Winston-Salem, NC, investigators are studying DMD-related heart disease by reprogramming skin cells to create heart cells in order to screen thousands of experimental compounds and drugs already approved by the Food and Drug Administration (FDA).  Another MDA-funded team in Philadelphia is exploring a new way to up-regulate utrophin, a muscle protein that may be able to stand in for the larger dystrophin protein that when absent causes DMD.  Plus, an MDA-sponsored team in Victoria, Australia is working to prevent extensive bone loss caused by corticosteroids, the only available treatment shown to slow the progression of DMD.

For ALS, a Houston-based team with MDA funding is investigating whether a combination drug treatment (Licofelone + Riluzole) works better than the first FDA-approved drug for ALS, riluzole.  Another group of MDA-sponsored investigators in Quebec City, Canada is looking for the earliest visible signs of ALS.  Finally, a San Diego team supported by MDA is using next-generation gene sequencing technology to better understand what makes ALS-causing mutations in two genes (TDP-43 + FUS/TUS) so crucial to the ALS disease process.

With tens of millions of Americans affected by type 2 diabetes and 30 percent of FA patients developing diabetes, a new MDA-funded project in Philadelphia to determine the exact mechanisms by which diabetes occurs in FA also could shed valuable insights into the causes of insulin resistance seen in people with type 2 diabetes.  

Other exciting initiatives by MDA-funded investigators include the Minneapolis-based effort to identify inhibitors of the DUX4 gene implicated in FSHD, and to quickly test promising compounds in a transgenic mouse model for that disease; and, a Miami-based effort to find novel genes that cause more rare forms of SMA and to search for genetic modifiers of the disease-causing genes.

About MDAMDA is the nonprofit agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research.  The Association also provides comprehensive healthcare and support services, advocacy and education.

In addition to funding more than 300 research teams worldwide, MDA maintains a national network of some 200 hospital-affiliated clinics; facilitates hundreds of support groups for families affected by neuromuscular diseases; and provides extraordinary local summer camp opportunities for thousands of youngsters fighting progressive muscle diseases.  MDA is the first nonprofit to receive a Lifetime Achievement Award from the American Medical Association "for significant and lasting contributions to the health and welfare of humanity."

For more information about the Association visit  See MDA's award-winning "Make a Muscle, Make a Difference"® PSA.


SOURCE Muscular Dystrophy Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy
2. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
3. Parent Project Muscular Dystrophy Awards $750,000 Grant to Sildenafil/Taladafil Study
4. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
5. AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedys Disease)
6. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
7. International Research Team Closes In On Cause of Common Form of Muscular Dystrophy
8. The SCOOTER Store Donates Scooter to High School Student With Muscular Dystrophy
9. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
10. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
11. Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:10/9/2015)... LAUSANNE , Schweiz, October 9, 2015 Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr.   ... --> Der " JCA-Mauvernay Award   ... und Dr.   Junko Takita    ™ ...
(Date:10/8/2015)... England and PITTSBURGH , ... ), a leading global pharmaceutical company, will host a ... at 5:00 pm ET to review the value ... (NYSE: PRGO ; TASE) through Mylan,s offer to ... a comprehensive presentation which outlines the compelling proposition for ...
(Date:10/8/2015)... , Oct. 8, 2015  The National Heart, ... $40 million to the Broad Institute of MIT ... of 20,000 individuals, as well as data to ... profiling. Trans-Omics for Precision Medicine ... toward a larger initiative, which will use whole ...
Breaking Medicine Technology:
... Cephalon, Inc. (Nasdaq: CEPH ) today provided notice ... Notes due 2014 (the "2014 Notes") and 2.00 percent ... in respect of the Merger (as defined below) of ... Industries Ltd., an Israeli corporation ("Parent"), the consummation of ...
... The Plasma Protein Therapeutics Association (PPTA) ... temporary and proposed regulations implementing the ... and fails to take into account concerns expressed ... narrow definition of an "orphan drug" disproportionally affects ...
Cached Medicine Technology:
(Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... ... Smoke alarms can save lives. In fact, according to the National Fire ... home fires in half. As part of Fire Prevention Week, Amica Insurance ... , Half of home fire deaths result from fires reported between 11 p.m. and ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance Agency, a family ... initiating a combined charity effort with Animal Rescue New Orleans in an effort ... , Animal Rescue New Orleans is a non-profit organization committed to rescuing and ...
Breaking Medicine News(10 mins):
... so does survival, study finds , MONDAY, Feb. 8 (HealthDay ... with increased risk of death, researchers say. , In a ... again at age 89 in a group of 555 participants ... at 85 and 89 years, and a greater decline in ...
... ... Strash, FACHE, Chief Executive Officer with Oro Valley Hospital, on critical issues facing healthcare ... ... timely communication among different segments of the medical community, Jackson & Coker ( ...
... , CINCINNATI , Feb. 8 Three ... "about right," according to a study of more than 65,000 ... of obesity over the past several years, the number of ... 1999 and 2007," says Nicholas M. Edwards , MD, ...
... triggering bone formation , MONDAY, Feb. 8 (HealthDay News) -- ... osteoporosis in lab mice and rats, a new study has ... gut hinders bone formation. Most current drugs for osteoporosis only ... "New therapies that inhibit the production of serotonin in the ...
... BETHESDA, Md. , Feb. 8 /PRNewswire-Asia/ ... Western healthcare,products and services in the People,s Republic of China , today ... , , Financial Highlights:, -- Revenue in ... over year to $46.5 million;, -- Net ...
... ... McDonald, have formed One2One Partners. The firm creates customized programs that strengthen the relationship ... an engaged workforce and minimize the threat of third-party intervention, regardless of potential legislation ... ...
Cached Medicine News:
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
Dnase-free, with an integral filter to protect against carry over and contamination from aerosols...
Medicine Products: